Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research coll...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 West 4th Ave, Vancouver, Canada

UgoGreg Feb. 28 at 9:49 PM

$ABCL https://youtu.be/ygBN8MilTyc

0 · Reply

raccoonblackbear Feb. 28 at 4:22 PM

$ABCL just when things were looking to break $4... war announcement. Let's see how the market fares on Monday.

1 · Reply

JennyRowes Feb. 28 at 3:34 PM

$ABCL is this correct? > $ 20M purchased and no sales in the last 5 years?? https://www.secform4.com/insider-trading/1703057.htm

1 · Reply

Kaykay610 Feb. 28 at 1:49 PM

$ABCL we are just building in silence!!

1 · Reply

Bessytibne Feb. 28 at 10:14 AM

$ABCL AI driven biotech research advancing

0 · Reply

hichemben Feb. 28 at 8:56 AM

$ABCL Andrew Booth (CFO) made an "open-market" purchase yesterday, Thermopylae Holdings Ltd. is a 10% owner and a primary investment vehicle for AbCellera’s founder and CEO, Carl Hansen. Super #Bullish signal for a solid reversal🚀

0 · Reply

snowPOW Feb. 28 at 2:40 AM

$ABCL great news! Insider Buying

0 · Reply

sogenerous Feb. 28 at 2:01 AM

$ABCL nice insider buys by CEO 177k and 42k CFO. I am holding 1/3 my at the bottom purchae from 2025 still

0 · Reply

tkstockpicker Feb. 28 at 12:44 AM

$ABCL Should now be support.

1 · Reply

desiguy Feb. 28 at 12:40 AM

$ABCL Carl bought 177K shares on the market

1 · Reply

AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 4:05 PM EST - 4 days ago

AbCellera Reports Full Year 2025 Business Results

Feb 11, 2026, 4:05 PM EST - 17 days ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Jan 22, 2026, 4:05 PM EST - 5 weeks ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 14, 2026, 9:16 PM EST - 6 weeks ago

AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 9:00 AM EST - 6 weeks ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Dec 18, 2025, 9:00 AM EST - 2 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 2 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 8, 2025, 1:37 PM EST - 2 months ago

AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Nov 22, 2025, 12:23 AM EST - 3 months ago

AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 10, 2025, 9:00 AM EST - 3 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 7, 2025, 7:16 PM EST - 4 months ago

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 4 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 5 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 6, 2025, 7:35 AM EDT - 5 months ago

AbCellera Biologics: Entering Growth Phase After A Pause

Sep 29, 2025, 4:05 PM EDT - 5 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 10, 2025, 9:07 AM EDT - 6 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Aug 27, 2025, 9:00 AM EDT - 6 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 7 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 7:48 PM EDT - 7 months ago

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 7 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Jul 7, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

May 30, 2025, 1:00 PM EDT - 9 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 10 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 10 months ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 10 months ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 10:33 PM EDT - 10 months ago

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 10 months ago

AbCellera Reports Q1 2025 Business Results

Apr 29, 2025, 3:00 PM EDT - 10 months ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 8, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Feb 27, 2025, 11:26 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 23, 2024, 4:39 PM EST - 1 year ago

AbCellera Biologics: Still A Concept Stock

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 7:22 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 14, 2024, 12:04 PM EDT - 1 year ago

AbCellera: A Platform To Pipeline Transition

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

Aug 23, 2024, 4:43 AM EDT - 1 year ago

AbCellera: A Waiting Game With High Uncertainty

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

UgoGreg Feb. 28 at 9:49 PM

$ABCL https://youtu.be/ygBN8MilTyc

0 · Reply

raccoonblackbear Feb. 28 at 4:22 PM

$ABCL just when things were looking to break $4... war announcement. Let's see how the market fares on Monday.

1 · Reply

JennyRowes Feb. 28 at 3:34 PM

$ABCL is this correct? > $ 20M purchased and no sales in the last 5 years?? https://www.secform4.com/insider-trading/1703057.htm

1 · Reply

Kaykay610 Feb. 28 at 1:49 PM

$ABCL we are just building in silence!!

1 · Reply

Bessytibne Feb. 28 at 10:14 AM

$ABCL AI driven biotech research advancing

0 · Reply

hichemben Feb. 28 at 8:56 AM

0 · Reply

snowPOW Feb. 28 at 2:40 AM

$ABCL great news! Insider Buying

0 · Reply

sogenerous Feb. 28 at 2:01 AM

$ABCL nice insider buys by CEO 177k and 42k CFO. I am holding 1/3 my at the bottom purchae from 2025 still

0 · Reply

tkstockpicker Feb. 28 at 12:44 AM

$ABCL Should now be support.

1 · Reply

desiguy Feb. 28 at 12:40 AM

$ABCL Carl bought 177K shares on the market

1 · Reply

Rastafari Feb. 27 at 11:35 PM

$ABCL Andrew Booth buying the stock on the market is very positive. This is a from an AI query, take it for what it’s worth! The sources we retrieved emphasize: • Insiders buy when they believe the stock is undervalued. Insider Trad... • Elevated insider buying relative to selling often precedes market uptrends. GuruFocus These patterns imply that when a CFO buys: • The probability of positive 12‑month performance increases, • And the magnitude of outperformance tends to be meaningful compared to the market baseline. A realistic probability estimate (based on aggregated insider‑buying research) While not CFO‑specific, the broader insider‑buying literature suggests: Outcome over next 12 months Approx. probability (historical studies) Stock is higher 60–70% likelihood Stock is lower 30–40% likelihood

1 · Reply

TheinvestmetABCD Feb. 27 at 10:47 PM

$ABCL Andrew and me probably bought at the same time :) Biggest buy and hold of the century, mark my word they will be one of the biggest pahrma giants in the future! My two biggest positions ABCL and GLSI are both printing (both managements are believing in their success by buying on the open market). GLSI more short term potential and ABCL highest long term potential.

1 · Reply

Odoji Feb. 27 at 10:06 PM

$ABCL 💉

0 · Reply

TheDrunkTrader69 Feb. 27 at 9:40 PM

$ABCL $$$$$

0 · Reply

DeMampCamp Feb. 27 at 9:02 PM

$ABCL What an outstanding close for such a bloody day! Cheers all, have a wonderful weekend!

0 · Reply

Samb2344 Feb. 27 at 8:54 PM

$ABCL back to $4S

0 · Reply

SocioCobb Feb. 27 at 8:53 PM

$ABCL CFO ready to go!

0 · Reply

8008track Feb. 27 at 8:20 PM

$ABCL people sell for a million reasons but they buy for one

0 · Reply

hichemben Feb. 27 at 8:02 PM

$ABCL 2026 is our year 🙌🏼 to the moon🚀💎

0 · Reply

UncleTomFlorida Feb. 27 at 7:54 PM

$ABCL CFO Booth acquires 42,600 shares today https://d18rn0p25nwr6d.cloudfront.net/CIK-0001703057/bb8415e4-5e03-4904-bd97-3bf36985e8a5.pdf

1 · Reply

TheTradeXchange Feb. 27 at 7:49 PM

FORM 4P $ABCL - AbCellera Biologics Inc. OFFICER - Chief Financial Officer: Booth Andrew P | 42,600 | $3.42 | $145,692

0 · Reply

Rastafari Feb. 27 at 1:25 PM

$ABCL Abcellera is hiring for these positions: Quality, Compliance & Manufacturing • Quality Control Technician (contract) — supporting QC lab operations and documentation. • Quality Control Manager — leading QC operations, especially microbiology. • Utilities Systems Operator — manufacturing support role. • Logistics & Warehouse Operators (contract) — lab supply/materials operations. Why? It is clear that they are ramping up specialist role to meet quality requirements set by FDA, additionally, why are they hiring for warehouse operators? One can only assume that they are ramping up for shipment of drugs that are approved. Just my two cents, as I tried to be inspector Clouseau😁

1 · Reply

Market Cap	1.09B
Revenue (ttm)	28.83M
Net Income (ttm)	-162.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-564.90%
Debt to Equity Ratio	0.00

Volume	5,382,600
Avg Vol	4,425,882
Day's Range	N/A - N/A
Shares Out	303.16M
Stochastic %K	98%
Beta	0.81
Analysts	Strong Sell
Price Target	$8.43